While COVID-19 may seem less prevalent than during the height of the pandemic five years ago, the virus continues to circulate. Recent data from the SiVIRA surveillance system indicates a syndromic rate of 1.8 cases per 100,000 inhabitants, with a positivity rate of 0.7%. The proxy incidence rate is currently at 3.5 cases per 100,000 inhabitants, slightly higher than previous reports, though a significant surge is not yet expected in the coming months.
Recognizing the ongoing presence of the virus, the Spanish Ministry of Health recently launched a public awareness campaign and released a report detailing the benefits of COVID-19 vaccination since the program’s inception over five years ago. This effort underscores the importance of continued vigilance and preventative measures against respiratory illnesses.
Vaccines Saved Lives
According to the Ministry of Health’s report, COVID-19 vaccines are estimated to have saved 127,000 lives in Spain and reduced mortality by 64% between December 2020 and March 2023. Among individuals over the age of 60, vaccine effectiveness in preventing death was 97% with mRNA vaccines and 88% in preventing hospitalization or ICU admission during the same period. These findings highlight the substantial impact of vaccination on reducing severe outcomes.
To date, Spanish health authorities report that nearly 106 million doses of COVID-19 vaccines have been administered, with approximately 41 million people having completed the primary vaccination series, according to data from the Ministry of Sanidad.
Prioritizing Vaccination for Vulnerable Groups
Based on the positive vaccination data and proven effectiveness, the Ministry of Health’s report includes recommendations for protecting against the virus during the current vaccination season. Priority is given to individuals aged 70 and older, particularly those with increased vulnerability, including immunocompromised patients, individuals with serious chronic conditions, and those living in institutional settings, as well as other high-risk groups.
Annual Booster Dose Recommended
The general recommendation for this target population is a single annual booster dose, regardless of the number of previous doses received or prior coronavirus infections, with a recommended interval of at least three months since the last dose or infection. The Ministry of Health extends this interval to six months if the last dose was the Bimervax vaccine, developed by HIPRA.
Spanish-Developed Vaccine Now Available
This vaccination campaign marks a milestone with the availability of a 100% Spanish-developed COVID-19 vaccine, which began distribution to health centers across the country last November. The vaccine is adapted to the LP.8.1 variant and utilizes a protein-based technology, offering a safe and effective alternative to mRNA vaccines.
HIPRA also signed an agreement with the European Commission’s Health Emergency Preparedness and Response Authority (HERA) in October to supply up to 4 million doses of the Spanish vaccine to EU member states over a period of up to two years.
Vaccination for Healthcare Workers and Caregivers
The report also outlines vaccination recommendations for healthcare and social care professionals, as well as individuals living with or caring for high-risk individuals. Access to vaccination is recommended as a personal protective measure, depending on the current epidemiological situation.
Co-Administration with Other Vaccines
Regarding co-administration with vaccines for other respiratory infections, such as influenza, the Ministry specifies that COVID-19 vaccines can be administered concurrently within the target population. While the campaign typically begins in late September and throughout October, individuals who have not yet received the updated seasonal vaccine can be vaccinated outside of the campaign timeframe, respecting recommended intervals.
